Panelists. Panelists Drug-Coated Balloon for PAD.

Slides:

Advertisements

Similar presentations

Drug Coated Balloons for PAD William B. Newton III, MD Assistant Professor of Surgery Department of Vascular and Endovascular Surgery.

Advertisements

Angelo Cioppa, MD  I have the following potential conflicts of interest to report:  Research contracts  Consulting  Employment in industry  Stockholder.

UpdateDEB Lesions Learned from the Trials and Daily Clinical Practice Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden.

University of Modena and Reggio Emilia Vascular Surgery – Director: prof. Coppi Silingardi R. Veronesi J. Gennai S.

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard

Introduction. Practical Perspectives in the Surgical Management of Parkinson Disease: LCIG.

The Invatec Program Features and Clinical Trials

Lutonix® Paclitaxel-Coated Balloon to Treat Obstructive Lesions in the Superficial Femoral and Popliteal Arteries Preliminary Six-Month Results from.

The (Potential) Role of Drug Eluting Balloons in BTK Interventions

Eric J Dippel, MD FACC Davenport, Iowa, USA February 19, 2017

Drug-Coated Balloons in Peripheral Artery Disease

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Renal Denervation Two Late-Breaking Clinical Trials.

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

An Endocrinology Clinic in Dyslipidemia

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

US Guidelines US Guidelines Low-risk Patients.

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Emergency Management of NOAC Bleeding

PAD Patients vs Post-ACS Patients:

SGLT2 Inhibitors in Phase 3 Trials

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Surveying the Safety of NOACs in the Real World

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

بسم الله الرحمن الرحيم الموضوع:الوضوء صفته وفرائضه وسننه

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Managing CINV and Cachexia

Diabetes Increases Risk of CVD

PAH Therapy Revisited.

VTE Treatment Conventional Approach

Antithrombotic Protection in CAD and HF

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

Drug-Coated Balloons:

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Oral Anticoagulation in AF

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Learning Objectives Metabolic Abnormalities Associated With T2D.

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.

Aspirin and Cardioprevention in 2018

Identifying High-Risk AF Patients

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

CAD and HF Often Coexist

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Controlling Elevated Blood Pressure

Can Drug-Coated Balloons Be a Solution for Complex Peripheral Lesions?

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Primary safety endpoint

Clinical Comparisons in CTEPH

Patient and Clinician Perspectives on Preventive Therapy for Migraine

What's New in Oral Combination Therapy for Type 2 Diabetes?

My PAH Patient.

Panelists. Panelists Drug-Coated Balloon for PAD.

PCSK9 Inhibitors and Real-World Evidence

The Power of As-Treated Analyses

Translating Data From Trial to Practice

Presentation transcript:

Panelists

Drug-Coated Balloon for PAD

Drug-Coated Balloon Technology

DCB Drug Delivery

Elements of Using the Drug-coated Balloon

Efficacy of Drug-coated Balloons

End Point Terminology

DCB Trial Results

IN.PACT SFA Trial Efficacy and Safety

Differences in TLR Thoughts?

Factors Affecting DCB Use

DEFINITIVE AR Conclusion

IN.PACT Global Registry

Primary Patency Diabetics vs Nondiabetics

IN.PACT DEEP Trial

Future Trials Where Do We Go From Here?

Abbreviations

References

References (cont)

References (cont)

References (cont)